MEDIUM confidence: 100% data completeness, but the composite (50) sits in the indecisive 30–70 range — strong-buy and short calls require a more decisive composite. What does confidence mean?
Technical context for active traders — derived from price, the 50/200-day moving averages, the 52-week range, and recent volume. Not part of the QScore.
Fama-French 5-factor (2×3) + Momentum, monthly OLS with Newey-West errors. Bars show signed factor betas; faded bars/figures aren't statistically significant.
Dated events from the market calendar; the “also watch” items are AI-generated observations from QScoring data. Informational only — not investment advice, and dates can change.
AI classification of policy/regulatory sensitivity from the company's sector, industry, and business description. Exposure/sensitivity only — not a political opinion, a prediction of government action, or investment advice. As of 2026-07-10.
Avg target $67 (last qtr, 29 analysts) → $64 (last mo, 14) (-4.3%).
Buy-rated share 89% → 84% over ~3 months (-5pp).
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jul 2026 | $0.83 | $0.86 | +3.0% |
| Apr 2026 | $0.79 | $0.80 | +1.5% |
| Feb 2026 | $0.78 | $0.80 | +2.4% |
| Oct 2025 | $0.71 | $0.75 | +5.0% |
| Jul 2025 | $0.72 | $0.75 | +3.4% |
| Apr 2025 | $0.67 | $0.75 | +11.4% |
| Feb 2025 | $0.66 | $0.70 | +6.5% |
| Oct 2024 | $0.59 | $0.63 | +7.1% |
Net buyback (repurchases less issuance) ÷ market cap, plus trailing dividend yield.
Net insider $9.9M over 180 days (9 open-market buys, 0 sells). Insider buying is the informative signal; routine selling is normal.
Short interest, days-to-cover, and institutional-ownership change require a data-plan upgrade (not yet available).
Forward-return IC, quintile spread & hit rate publish on /performance as the tracking panel accrues enough no-look-ahead history.
Working the DCF backward: holding the assumptions below, this is the free-cash-flow growth today's price implies over the next 10 years. It is a read on the price's embedded expectations — not a fair-value or target price.
The price implies FCF growth above the analyst consensus of 7.2%/yr (revenue basis).
Base free cash flow $2.7B (avg FY2023–FY2025; latest year $3.7B) · equity value $76.7B · levered FCF discounted at the cost of equity. Reverse DCF is illustrative, not advice.
| Metric (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $11.9B— | $12.7B+6.7% | $14.2B+12.3% | $16.7B+17.6% | $20.1B+19.9% |
| EPS (dil.) | $0.69— | $0.45-35.1% | $1.07+140.6% | $1.25+16.5% | $1.94+55.2% |
| Free Cash Flow | $1.3B— | $914M-30.5% | $1.7B+86.3% | $2.6B+55.3% | $3.7B+38.3% |
| Gross Margin | 62.8% | 60.8%-1.9pp | 62.0%+1.2pp | 61.3%-0.7pp | 69.0%+7.7pp |
| Operating Margin | 16.2% | 14.4%-1.8pp | 15.3%+0.9pp | 15.7%+0.4pp | 19.8%+4.0pp |
| Net Margin | 8.7% | 5.5%-3.2pp | 11.2%+5.7pp | 11.1%-0.1pp | 14.4%+3.3pp |
Absolute figures with year-over-year change. Margins show the level with the change in percentage points (pp). “n/m” = not meaningful (prior ≤ 0); ⚠ marks a large percentage off a small base — read the dollar figure.
The QScore of 50 for Boston Scientific Corporation suggests a neutral outlook, with the stock's long-term and short-term scores diverging slightly, at 53 and 48, respectively. The stock scores high on profitability, with a return on equity near 15%, and exhibits reasonable value, trading at a P/E of 20.8. However, momentum is a concern, with a 12-month return of -49.5% and a bearish moving average trend, which weighs down the overall score.